Outlook Therapeutics Inc [OTLK] stock prices are up 18.24% to $2.01 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The OTLK shares have gain 44.60% over the last week, with a monthly amount drifted -58.90%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Outlook Therapeutics Inc [NASDAQ: OTLK] stock has seen the most recent analyst activity on December 02, 2024, when Chardan Capital Markets downgraded its rating to a Neutral. Previously, BTIG Research upgraded its rating to Buy on March 27, 2024, and kept the price target unchanged to $50. On February 15, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $3 on the stock. Guggenheim upgraded its rating to a Buy. CapitalOne upgraded its rating to a Overweight but $5 remained the price target by the analyst firm on December 27, 2023. H.C. Wainwright downgraded its rating to Neutral for this stock on August 31, 2023, and downed its price target to $1. In a note dated August 31, 2023, Chardan Capital Markets downgraded an Neutral rating on this stock.
The stock price of Outlook Therapeutics Inc [OTLK] has been fluctuating between $0.87 and $12.85 over the past year. Outlook Therapeutics Inc [NASDAQ: OTLK] shares were valued at $2.01 at the most recent close of the market.
Analyzing the OTLK fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -2.0, Equity is 1.47 and Total Capital is -13.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.73 points at the first support level, and at 1.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.24, and for the 2nd resistance point, it is at 2.46.
Ratios To Look Out For
It’s worth pointing out that Outlook Therapeutics Inc [NASDAQ:OTLK]’s Current Ratio is 0.64. Further, the Quick Ratio stands at 0.64, while the Cash Ratio is 0.75.
Transactions by insiders
Recent insider trading involved KENYON LAWRENCE A, Chief Financial Officer, that happened on Sep 26 ’24 when 5000.0 shares were purchased. Director, Haddadin Yezan Munther completed a deal on Mar 28 ’24 to buy 1882.0 shares. Meanwhile, CHIEF COMMERCIAL OFFICER Evanson Jeff bought 62484.0 shares on Mar 07 ’24.
